We are live on ! Find out more
BXRX

Baudax Bio, Inc. Common Stock
BXRX

Delisted

BXRX was delisted on the 15th of November, 2023.

Back to rankings

26 hedge funds and large institutions have $4.12M invested in Baudax Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

16% less funds holding

Funds holding: 31 → 26 (-5)

26% less capital invested

Capital invested by funds: $5.58M → $4.12M (-$1.46M)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
26
Holders Change
-5
Holders Change %
-16.13%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
7
Closed
7
Calls
$180K
Puts
–
Net Calls
+$180K
Net Calls Change
-$164K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$167K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$91.3K
3
VF
Virtu Financial
New York
+$65.2K
4
UBS Group
UBS Group
Switzerland
+$40K
5
BlackRock
BlackRock
New York
+$12.2K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$225K
2
Goldman Sachs
Goldman Sachs
New York
-$115K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21.7K
4
PCM
Pinz Capital Management
New York
-$16K
5
Northern Trust
Northern Trust
Illinois
-$11.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.11M +$7.83K +9 +0.3%
BlackRock
2
BlackRock
New York
$749K +$12.2K +14 +1%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$383K +$91.3K +105 +27%
Millennium Management
4
Millennium Management
New York
$184K +$167K +192 +457%
State Street
5
State Street
Massachusetts
$160K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$90K -$10.4K -12 -9%
Northern Trust
7
Northern Trust
Illinois
$82K -$11.3K -13 -11%
VF
8
Virtu Financial
New York
$70K +$65.2K +75 +536%
EDRH
9
Edmond de Rothschild Holding
Switzerland
$56K – – –
IC
10
Ikarian Capital
Texas
$53K -$2.61K -3 -4%
UBS Group
11
UBS Group
Switzerland
$36K +$40K +46 New
MML Investors Services
12
MML Investors Services
Massachusetts
$32K – – –
Osaic Holdings
13
Osaic Holdings
Arizona
$26K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$18K -$6.09K -7 -23%
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$11K -$870 -1 -6%
LPL Financial
16
LPL Financial
California
$10K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$10K +$11.3K +13 New
ASN
18
Advisory Services Network
Georgia
$9K -$3.48K -4 -27%
SIP
19
Stoneridge Investment Partners
Pennsylvania
$8K – – –
Manulife (Manufacturers Life Insurance)
20
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K – – –
Victory Capital Management
21
Victory Capital Management
Texas
$7K – – –
GLA
22
Good Life Advisors
Pennsylvania
$6K – – –
Group One Trading
23
Group One Trading
Illinois
$5K +$1.74K +2 +40%
Wells Fargo
24
Wells Fargo
California
$1K -$1.74K -2 -67%
1832 Asset Management
25
1832 Asset Management
Ontario, Canada
$1K – – –
1
2

BXRX Hedge Fund Activity: Q3 2021 in Review

26 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q3 2021, worth a combined $4.12M — down 26% from $5.58M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BXRX and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was Millennium Management, adding an estimated $167K. The largest seller was Morgan Stanley, exiting entirely with an estimated $225K sold.

  • 26 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q3 2021, down from 31 in Q2 2021.
  • Funds reported $4.12M of Baudax Bio, Inc. Common Stock stock for Q3 2021, down 26% quarter-over-quarter.
  • 2 funds opened new Baudax Bio, Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of -5 holders.
  • The largest Baudax Bio, Inc. Common Stock buyer in Q3 2021 was Millennium Management, an estimated $167K added.
  • The largest Baudax Bio, Inc. Common Stock seller in Q3 2021 was Morgan Stanley, an estimated $225K sold.

Based on aggregated 13F filings for Q3 2021.